Garrett Winslow
CIK: 0001803773
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Damora Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jul 6, 2026DMRA
Damora Therapeutics, Inc.
Sale(S)Direct245 shares at avg. $29.98$7K - Jul 3, 2026DMRA
Damora Therapeutics, Inc.
Exercise(M)Direct680 shares- - Mar 23, 2026DMRA
Damora Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
250K shares- - Jan 2, 2026GLTO
Galecto, Inc.
Exercise(M)Direct680 shares- - Jan 2, 2026GLTO
Galecto, Inc.
Sale(S)Direct255 shares at avg. $21.38$5K - Jul 3, 2025GLTO
Galecto, Inc.
Sale(S)Direct260 shares at avg. $3.39$881.4 - Jul 3, 2025GLTO
Galecto, Inc.
Exercise(M)Direct680 shares- - Jan 3, 2025GLTO
Galecto, Inc.
Award(A)DirectStock Option (right to buy)
6K shares- - Jan 3, 2025GLTO
Galecto, Inc.
Exercise(M)Direct1.3K shares- - Jan 3, 2025GLTO
Galecto, Inc.
Sale(S)Direct471 shares at avg. $5.60$3K - Oct 9, 2024GLTO
Galecto, Inc.
Award(A)DirectStock Option (right to buy)
15.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 6, 2026 | DMRA Damora Therapeutics, Inc. | Sale(S) | 245 | $29.98 | $7,345 | Direct |
| Jul 3, 2026 | DMRA Damora Therapeutics, Inc. | Exercise(M) | 680 | - | $0 | Direct |
| Mar 23, 2026 | DMRA Damora Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 250,000 | - | - | Direct |
| Jan 2, 2026 |  GLTO Galecto, Inc. | Exercise(M) | 680 | - | $0 | Direct |
| Jan 2, 2026 | GLTO Galecto, Inc. | Sale(S) | 255 | $21.38 | $5,452 | Direct |
| Jul 3, 2025 | GLTO Galecto, Inc. | Sale(S) | 260 | $3.39 | $881 | Direct |
| Jul 3, 2025 | GLTO Galecto, Inc. | Exercise(M) | 680 | - | - | Direct |
| Jan 3, 2025 | GLTO Galecto, Inc. | Award(A) Stock Option (right to buy) | 6,000 | - | - | Direct |
| Jan 3, 2025 | GLTO Galecto, Inc. | Exercise(M) | 1,320 | - | $0 | Direct |
| Jan 3, 2025 | GLTO Galecto, Inc. | Sale(S) | 471 | $5.60 | $2,638 | Direct |
| Oct 9, 2024 | GLTO Galecto, Inc. | Award(A) Stock Option (right to buy) | 15,600 | - | - | Direct |
1-11 of 11 transactions
About Winslow Garrett
Winslow Garrett (SEC CIK 0001803773) files insider reports with the SEC as General Counsel of Damora Therapeutics, Inc. (DMRA).
Signal8 holds 6 ownership filings by Winslow Garrett, all Form 4s, filed between Oct 11, 2024 and Jul 7, 2026. Those filings report 11 transactions, from Oct 9, 2024 to Jul 6, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Winslow Garrett's filings is in WALTHAM, MA.
Recent filings by Winslow Garrett
- Jul 6, 2026: Open-market sale of DMRA shares (Form 4, code S).
- Jul 3, 2026: Option exercise of DMRA shares (Form 4, code M).
- Mar 23, 2026: Grant or award of DMRA derivative securities (Form 4, code A).
- Jan 2, 2026: Option exercise of GLTO shares (Form 4, code M).
- Jan 2, 2026: Open-market sale of GLTO shares (Form 4, code S).
Other insiders filing for Damora Therapeutics, Inc. (DMRA)
- Jarrett Jennifer, Director, President and CEO
- Cheng Andrew, Director
- Burkavage Brian, SVP, Finance
- Turtle Cameron, Director
- Landsittel Michael, Director
- Fairmount Funds Management LLC, Director